Korean J Med.  2014 Feb;86(2):242-246.

Acute Myeloid Leukemia with Persistent Marrow Aplasia after Chemotherapy Treated with Reduced-Intensity Allogeneic Stem Cell Transplantation

Affiliations
  • 1Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea. alertjun@hanmail.net
  • 2Department of Laboratory Medicine, Gachon University School of Medicine, Incheon, Korea.

Abstract

Persistent bone marrow aplasia after intensive chemotherapy is uncommon, but is one of the fatal complications in patients with acute myeloid leukemia (AML). Although allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be contraindicated for patients who have hematologic diseases with serious infections, such as bacterial septicemia or invasive fungal diseases, combined with prolonged neutropenia due to frequent morbidity and mortality, such risks can be overcome by non-myeloablative conditioning and best supportive care. Here, we report an AML patient with persistent marrow aplasia after induction therapy, treated successfully with reduced-intensity allogeneic HSCT despite severe bacterial and fungal infections.

Keyword

Acute myeloid leukemia; Stem cell transplantation; Aplastic anemia; Neutropenia; Chemotherapy

MeSH Terms

Anemia, Aplastic
Bone Marrow*
Drug Therapy*
Hematologic Diseases
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute*
Mortality
Neutropenia
Sepsis
Stem Cell Transplantation*
Stem Cells*
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr